About tofacitinib citrate
Janus kinase (JAK) inhibitor
Used for
- Rheumatoid arthritis
- Psoriatic arthritis
- Ulcerative colitis
- Other approved inflammatory conditions, depending on country
Usual adult dose
Usually 5 mg twice daily for arthritis; ulcerative colitis dosing varies by treatment phase and local guidance.
Usual dose in children
For juvenile idiopathic arthritis, typically 5 mg twice daily or weight-based equivalent, for children aged 2 years and older.
Common side effects
- Upper respiratory infections
- Headache
- Diarrhea
- Raised cholesterol or liver enzymes
Important warnings
- Serious infections, including tuberculosis, can occur.
- May increase risks of blood clots, major heart events, and certain cancers.
- Blood counts and liver tests may need monitoring.
- Avoid live vaccines during treatment.
Pregnancy
Avoid during pregnancy; human data are limited, and animal studies raise concern. Discuss pregnancy planning with a clinician.
Breastfeeding
Breastfeeding is not recommended during treatment or for at least 18 hours after the last immediate-release dose.
Interactions
- Strong CYP3A4 inhibitors, such as ketoconazole, can raise drug levels.
- Strong CYP3A4 inducers, such as rifampin, can lower drug levels.
- Avoid combining with biologic immune-suppressing medicines or potent immunosuppressants.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.